60 completed, 11 terminated, 8 unknown, 4 recruiting. 87 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 87 | Completed 60, Terminated 11, Unknown 8, Recruiting 4, Not yet recruiting 2, Active not recruiting 1, Withdrawn 1 |
Follow HIV Infection: new trials by email Literature Review of HIV Infection trials Research Report on HIV Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy - The RELAI Study Field-based LA-CAB/RPV - HIV Infection | Phase 4 | Not yet recruiting | University of North Carolina, Chapel Hill | 40 | 2027-01-01 | 2026-10-26 |
| Menopausal HT for Women Living With HIV (HoT) Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel - HIV Infection, Menopause | Phase 4 | Recruiting | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 105 | 2026-04-09 | 2026-05-22 |
| MAPS PrEP Van Study Pre-Exposure Prophylaxis (PrEP) - HIV Infection | Phase 4 | Completed | Duke University | 7 | 2025-09-17 | 2026-07-24 |
| Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up Dual therapy: darunavir/cobicistat + lamivudine, Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine - HIV Infection, Antiretroviral Therapy | Phase 4 | Recruiting | Instituto Mexicano del Seguro Social | 78 | 2025-07-10 | 2026-07-01 |
| Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience DTG/3TC, Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) - HIV Infection, Metabolic Syndrome | Phase 4 | Recruiting | Instituto Mexicano del Seguro Social | 124 | 2025-04-01 | 2025-06-26 |
| Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation Regimen:BIC+FTC+TAF - HIV Infection, HIV | Phase 4 | Not yet recruiting | National Center for AIDS/STD Control and Prevention, China CDC | 250 | 2025-02-28 | 2025-02-17 |
| Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico dual therapy, Standard Medical Therapy - HIV Infection | Phase 4 | Recruiting | José Antonio Mata Marín | 138 | 2023-11-09 | 2025-04-04 |
| Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC) - HIV Infection | Phase 4 | Active not recruiting | Professor Francois Venter | 1900 | 2023-05-19 | 2025-06-05 |
| Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial Recombinant Human Papillomavirus Nonavalent Vaccine - HIV Infection | Phase 4 | Completed | Fred Hutchinson Cancer Center | 97 | 2022-03-10 | 2026-07-02 |
| Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy Dihydroartemisinin-piperaquine - Drug-Drug Interaction, HIV Infection | Phase 4 | Completed | University of California, San Francisco | 194 | 2020-11-23 | 2025-03-14 |
| Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial Estradiol Vaginal Insert - HIV Infection, Vaginal Atrophy | Phase 4 | Completed | Kerry Murphy | 60 | 2020-09-01 | 2025-03-14 |
| Triple vs. Double Therapy in naïves HIV-Infected Patients Randomize - HIV Infection | Phase 4 | Unknown | Hospitales Universitarios Virgen del Rocío | 70 | 2020-03-10 | 2020-08-18 |
| Nevirapine / Lamivudine for HIV Maintenance Therapy Neviparine (NVP)/ Lamivudine (3TC) - HIV Infection, Antiretroviral Treatment | Phase 4 | Completed | Cantonal Hospital of St. Gallen | 201 | 2019-04-12 | 2025-06-10 |
| Linking Infectious and Narcology Care-Part II Rapid ART initiation, Pharmacotherapy for opioid use disorder, Strengths-based HIV case management - HIV Infection, Drug Use | Phase 4 | Completed | Boston Medical Center | 225 | 2018-09-19 | 2023-04-18 |
| RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection Rilpivirine + darunavir/cobicistat - HIV Infection | Phase 4 | Unknown | A.O. Ospedale Papa Giovanni XXIII | 1609 | 2017-02-01 | 2019-08-22 |
| Liraglutide for HIV-associated Neurocognitive Disorder Liraglutide - HIV Infection, Diabetes Mellitus Type 2 | Phase 4 | Terminated | Temple University | 4 | 2016-09-01 | 2022-07-29 |
| Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Patients PCV13, PPV23 - HIV Infection | Phase 4 | Unknown | Aghia Sophia Children's Hospital of Athens | 40 | 2015-12-01 | 2017-02-02 |
| Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy Treatment simplification - HIV Infection | Phase 4 | Completed | University of British Columbia | 10 | 2014-10-01 | 2017-11-06 |
| Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir raltegravir and atazanavir and ritonavir, tenofovir/emtricitabine and atazanavir and ritonavir - HIV Infection, Osteopenia | Phase 4 | Terminated | Giovanni Di Perri | 4 | 2014-09-01 | 2018-10-17 |
| Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study Sofosbuvir, Ribavirin, and Stribild - Hepatitis C Infection, HIV Infection | Phase 4 | Completed | Saint Michael's Medical Center | 10 | 2014-07-01 | 2016-08-04 |
Showing 20 of 87. Sign in to see all of them.
HIV Infections (87) · Acquired Immunodeficiency Syndrome (8) · Hepatitis C (3) · Lipodystrophy (3) · Tuberculosis (3) · Cardiovascular Diseases (2) · Diabetes Mellitus, Type 2 (2) · Dyslipidemias (2) · Hepatitis B (2) · Hepatitis C, Chronic (2) · Infections (2) · Malaria (2) · Metabolic Syndrome (2) · Aging, Premature (1) · Atherosclerosis (1)
Blood-Borne Infections (87) · Communicable Diseases (87) · Genital Diseases (87) · Immunologic Deficiency Syndromes (87) · Retroviridae Infections (87) · Sexually Transmitted Diseases (87) · Urogenital Diseases (87) · Immune System Diseases (86) · Lentivirus Infections (86) · RNA Virus Infections (86) · Sexually Transmitted Diseases, Viral (86) · Virus Diseases (86) · Infections (85) · Metabolic Diseases (9) · Nutritional and Metabolic Diseases (9)
Tenofovir (10) · Ritonavir (9) · efavirenz (9) · Emtricitabine (8) · Lamivudine (8) · Raltegravir Potassium (8) · Lopinavir (7) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (6) · Atazanavir Sulfate (5) · lopinavir-ritonavir drug combination (5) · Maraviroc (4) · abacavir (4) · abacavir, lamivudine drug combination (4) · Antiretroviral Therapy, Highly Active (3) · Darunavir (3)
GlaxoSmithKline (5) · Fundacion SEIMC-GESIDA (4) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (3) · Hospital Clinic of Barcelona (3) · University of British Columbia (3) · University of California, San Francisco (3) · University of Washington (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Instituto Mexicano del Seguro Social (2) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (2) · Pfizer (2) · Sociedad Andaluza de Enfermedades Infecciosas (2) · St Stephens Aids Trust (2) · Tufts University (2) · University of North Carolina, Chapel Hill (2)
United States (33) · Spain (17) · Brazil (8) · Uganda (8) · Canada (6) · Italy (6) · Switzerland (6) · Mexico (5) · Netherlands (5) · Peru (5) · Puerto Rico (5) · South Africa (5) · United Kingdom (5) · Australia (4) · Haiti (4)
Christine A Wanke, MD (2) · Federico Pulido, MD (2) · Felipe Garcia, PhD (2) · Abdel Babiker, PhD (1) · Adeodata Kekitiinwa (1) · Amy Justice, MD, PhD (1) · Ana Puga, MD (1) · Andrea De Luca, Prof (1) · Andy IM Hoepelman, MD (1) · Ann Duerr, MD, PhD (1) · Anna Wald, MD, MPH (1) · Barbara Moscicki, MD (1)
PMID 11813503, PMID 11915000, PMID 18097218, PMID 18256392, PMID 18697216, PMID 19349870, PMID 19358725, PMID 19532059, PMID 19542866, PMID 19581631, PMID 19906626, PMID 21350366, PMID 21384334, PMID 21419775, PMID 21422117, PMID 21951596, PMID 21998479, PMID 22010914, PMID 22228003, PMID 22405335, PMID 22848378, PMID 22918156, PMID 23277897, PMID 23362296, PMID 23386261, PMID 23589670, PMID 23646111, PMID 24988179, PMID 25582793, PMID 25711317, PMID 25711318, PMID 25711319, PMID 25711320, PMID 25711321, PMID 25711322, PMID 25711323, PMID 25711324, PMID 25711325, PMID 25711326, PMID 25711327, PMID 25711328, PMID 25711329, PMID 25711330, PMID 25711331, PMID 25711332, PMID 26062880, PMID 26062881, PMID 26192873, PMID 26908541, PMID 26994089
2008 (3), U01AI068632 (2), U01AI068636 (2), 2014 (1), 2019 (1), K23AG062400 (1), K23AI070078 (1), K23DK079789 (1), P30AI064518 (1), R01DA013806 (1), R01DA045547 (1), R01HD068174 (1), R01HL096585 (1), R01MH095507 (1), R34MH139436 (1)